-
Theranostics of Thyroid Cancer Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-03-19 Luca Giovanella MD PhD, Murat Tuncel MD PhD, Atena Aghaee MD PhD, Alfredo Campenni MD PhD, Armando De Virgilio MD PhD, Petra Petranović Ovčariček MD PhD
Molecular imaging is pivotal in evaluating and managing patients with different thyroid cancer histotypes. The existing, pathology-based, risk stratification systems can be usefully refined, by incorporating tumor-specific molecular and molecular imaging biomarkers with theranostic value, allowing patient-specific treatment decisions. Molecular imaging with different radioactive iodine isotopes (ie
-
Radiotheranostics Global Market and Future Developments Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-03-13 Akram Al-Ibraheem MD FRCP FEBNM FANMB, Richard Zimmermann PhD, Ahmed S. Abdlkadir MD, Ken Herrmann MD MBA
Radiotheranostics, a combination of diagnostic and therapeutic approaches, was first utilized in cancer management using radiopharmaceuticals to both image and selectively treat specific cancer subtypes nearly a century ago. Radiotheranostic strategies rooted in nuclear medicine have revolutionized the treatment landscape for individuals diagnosed with prostate cancer and neuroendocrine tumors in the
-
Imaging of Cardiac Sarcoidosis: An Update and Future Aspects Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-03-12 Petar Saric MD PharmD, John P. Bois MD, John R. Giudicessi MD PhD, Andrew N. Rosenbaum MD, Joanna E. Kusmirek MD, Grace Lin MD MBA, Panithaya Chareonthaitawee MD
Cardiac sarcoidosis (CS), an increasingly recognized disease of unknown etiology, is associated with significant morbidity and mortality. Given the limited diagnostic yield of traditional endomyocardial biopsy (EMB), there is increasing reliance on multimodality cardiovascular imaging in the diagnosis and management of CS, with EMB being largely supplanted by the use of F-fluorodeoxyglucose (FDG-PET)
-
Molecular Imaging in Soft-tissue Sarcoma: Evolving Role of FDG PET Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-03-02 Kip E. Guja MD PhD, Kristen N. Ganjoo MD, Andrei Iagaru MD
Soft tissue sarcomas are a rare and heterogenous group of tumors that account for 2% of all cancer-related deaths. Molecular imaging with FDG PET can offer valuable metabolic information to help inform clinical management of soft tissue sarcomas that is unique and complementary to conventional diagnostic imaging techniques. FDG PET imaging often correlates with tumor grade, can help guide biopsy, and
-
Cardiovascular Imaging in Women Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-02-23 Samia Massalha MD, John Kennedy PhD, Essam Hussein MD, Besma Mahida MD, Zohar Keidar MD PhD
Multimodality cardiovascular imaging is a cornerstone diagnostic tool in the diagnosis, risk stratification, and management of cardiovascular diseases, whether those involving the coronary tree, myocardial, or pericardial diseases in general and particularly in women. This manuscript aims to shed some light and summarize the very features of cardiovascular disease in women, explore their unique characteristics
-
Fibroblast Activation Protein Inhibitor (FAPI) PET Imaging in Sarcomas: A New Frontier in Nuclear Medicine Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-02-16 Francesco Giammarile, Peter Knoll, Diana Paez, Enrique Estrada Lobato, Adriana K. Calapaquí Terán, Roberto C. Delgado Bolton
-
Women's Health Update: Growing Role of PET for Patients with Breast Cancer Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-02-16 Gary A. Ulaner MD, Sofia Carrilho Vaz MD
Positron Emission Tomography (PET) has been growing in usage for patients with breast cancer, due to an increased number of FDA-approved PET radiotracers pertinent to patients with breast cancer as well as increased prospective evidence for the value of these agents. The leading PET radiotracer for patients with breast cancer is 18F-fluorodeoxyglucose (18F-FDG), which measures glucose metabolism. There
-
Neurological Disorders and Women's Health: Contribution of Molecular Neuroimaging Techniques Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-02-15 Ozgul Ekmekcioglu MD, Nathalie L. Albert MD, Kathrin Heinrich MD, Nelleke Tolboom MD, Donatienne Van Weehaeghe MD PhD, Tatiana Traub-Weidinger MD, Lutfiye Ozlem Atay MD, Valentina Garibotto MD, Silvia Morbelli MD
Sex differences in brain physiology and the mechanisms of drug action have been extensively reported. These biological variances, from structure to hormonal and genetic aspects, can profoundly influence healthy functioning and disease mechanisms and might have implications for treatment and drug development. Molecular neuroimaging techniques may help to disclose sex's impact on brain functioning, as
-
Letter From the Editors Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-02-14 M. Michael Sathekge MD PhD, Kirsten Bouchelouche MD DMSc
-
Letter From the Guest Editors Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-02-13 Laura Evangelista MD PhD, Ora Israel MD
-
Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-02-11 Tasnim Khessib MD, Priyanka Jha MBBS, Guido A. Davidzon MD, Andrei Iagaru MD, Jagruti Shah MBBS
Gynecologic malignancies, consisting of endometrial, cervical, ovarian, vulvar, and vaginal cancers, pose significant diagnostic and management challenges due to their complex anatomic location and potential for rapid progression. These tumors cause substantial morbidity and mortality, often because of their delayed diagnosis and treatment. An estimated 19% of newly diagnosed cancers among women are
-
Gastrin-releasing peptide receptor as a theranostic target in breast cancer: a systematic scoping review Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-02-10 Christina Baun MSc, Mohammad Naghavi-Behzad MD PhD, Malene Grubbe Hildebrandt MD PhD, Oke Gerke MSc PhD, Helge Thisgaard MSc PhD
The gastrin-releasing peptide receptor (GRPR) is known to be overexpressed in breast cancer, making it a promising target for both imaging and therapy within a theranostic framework. Various radioligands targeting GRPR have undergone investigation in preclinical and clinical studies related to breast cancer. This systematic scoping review aimed to assess the current evidence on GRPR-targeted radioligands
-
Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [18F]F-FDG Tracers Part II. [18F]F-FLT, [18F]F-FET, [11C]C-MET and Other Less-Commonly Used Radiotracers Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-02-07 Roya Eisazadeh MD FEBNM, Malihe Shahbazi-Akbari MD, Seyed Ali Mirshahvalad MD MPH FEBNM, Christian Pirich MD PhD, Mohsen Beheshti MD FEBNM FASNC
Following the previous part of the narrative review on artificial intelligence (AI) applications in positron emission tomography (PET) using tracers rather than F-fluorodeoxyglucose ([F]F-FDG), in this part we review the impact of PET-derived radiomics data on the diagnostic performance of other PET radiotracers, F-O-(2-fluoroethyl)-L-tyrosine ([F]F-FET), F-Fluorothymidine ([F]F-FLT) and C-Methionine
-
The Future Direction of Women in Nuclear Medicine and Nuclear Medicine in Women's Health Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-01-13 Laura Evangelista MD PhD, Priscilla Guglielmo MD, Agata Pietrzak PhD, Alexandra Maria Lazar MD, Luca Urso MD, Atena Aghaee MD, Elisabeth Eppard PhD
This work discusses the role of Nuclear Medicine for women's health, the role of women in the development of this emerging field and the various issues which arise from both. It emphasizes the importance of young women and their competing needs due to factors like pregnancy and work-related challenges. The objectives of this overview include improving imaging techniques, preserving fertility during
-
SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases Semin. Nucl. Med. (IF 4.9) Pub Date : 2024-01-03 Nazanin Zamani-Siahkali, Seyed Ali Mirshahvalad, Abolfazl Farbod, Ghasemali Divband, Christian Pirich, Patrick Veit-Haibach, Gary Cook, Mohsen Beheshti
Recent developments in hybrid SPECT/CT systems and the use of cadmium-zinc-telluride (CZT) detectors have improved the diagnostic accuracy of bone scintigraphy. These advancements have paved the way for novel quantitative approaches to accurate and reproducible treatment monitoring of bone metastases. PET/CT imaging using [18F]F-FDG and [18F]F-NaF have shown promising clinical utility in bone metastases
-
State of the Art Imaging of Osteoporosis Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-12-11 Michelle Chen, Maria Gerges, William Y. Raynor, Peter Sang Uk Park, Edward Nguyen, David H. Chan, Ali Gholamrezanezhad
Osteoporosis is a common disease, particularly prevalent in geriatric populations, which causes significant worldwide morbidity due to increased bone fragility and fracture risk. Currently, the gold-standard modality for diagnosis and evaluation of osteoporosis progression and treatment relies on dual-energy x-ray absorptiometry (DXA), which measures bone mineral density (BMD) and calculates a score
-
Letter From the Editors Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-12-06 Kirsten Bouchelouche, M Michael Sathekge
Abstract not available
-
How to Perform FAPI PET? An Expedited Systematic Review Providing a Recommendation for FAPI PET Imaging With Different FAPI Tracers Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-12-04 Morten Bentestuen, Surenth Nalliah, Marie M.K. Stolberg, Helle D. Zacho
This expedited systematic review aims to provide the first overview of the different Fibroblast activation protein inhibitor (FAPI) PET scan procedures in the literature and discuss how to efficiently obtain optimal FAPI PET images based on the best available evidence. The PubMed, Embase, Cochrane Library, and Web of Science databases were systematically searched in April 2023. Peer-reviewed cohort
-
What Role Does PET/MRI Play in Musculoskeletal Disorders? Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-12-02 Tugce Telli, Mélanie Desaulniers, Thomas Pyka, Federico Caobelli, Sophia Forstmann, Lale Umutlu, Wolfgang P. Fendler, Axel Rominger, Ken Herrmann, Robert Seifert
Musculoskeletal disorders of nononcological origin are one of the most frequent reasons for consultation. Patients suffering from musculoskeletal disorders also consult more than once for the same reason. This results in multiple clinical follow-ups after several radiological and serum examinations, the main ones including X-rays targeting the painful anatomical region and inflammatory serum parameters
-
Autoimmune Thyroid Diseases Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-12-02 Petra Petranović Ovčariček MD PhD, Rainer Görges MD PhD, Luca Giovanella MD PhD
Autoimmune thyroid diseases (AITDs) include a wide spectrum of thyroid diseases affecting more commonly women than men. The most frequent forms are Graves’ Disease (GD) and Hashimoto's thyroiditis / Autoimmune Thyroiditis (AIT), but there are also other immunogenic destructive forms of thyroiditis, that is, silent and postpartum thyroiditis. In the last decade, AITDs and other inflammatory thyroid
-
[18F]FDG-PET/CT in Polymyalgia Rheumatica: An Update and Future Aspects Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-11-28 Olivier Gheysens, Marie Péan de Ponfilly, Gaetane Nocturne, Raphaële Seror, Florent L. Besson, François Jamar
Polymyalgia rheumatica (PMR) is an inflammatory disorder usually diagnosed in patients older than 50 years of age. It is characterized by sudden onset pain and prolonged morning stiffness in the scapular and/or pelvic girdle, sometimes debilitating and accompanied by constitutional symptoms such as weight loss. In approximately 20% of the cases, it is linked to giant cell arteritis (GCAV) representing
-
PET/CT and SPECT/CT for Infection in Joints and Bones: An Overview and Future Directions Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-11-27 Kgomotso M.G. Mokoala, Honest Ndlovu, Ismaheel Lawal, Mike Machaba Sathekge
Infections of the bones and joints, if misdiagnosed, may result in serious morbidity and even mortality. A prompt diagnosis followed by appropriate management may reduce the socioeconomic impact of bone and joint infections. Morphologic imaging such as ultrasound and plain radiographs form the first line investigations, however, in early infections findings may be negative or nonspecific. Nuclear medicine
-
Novel Targets for Molecular Imaging of Inflammatory Processes of Carotid Atherosclerosis: A Systematic Review Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-11-23 Louise Maes, Louis Versweyveld, Nicholas R Evans, John J McCabe, Peter Kelly, Koen Van Laere, Robin Lemmens
Computed tomography angiography (CTA), magnetic resonance angiography (MRA) and 18F-FDG-PET have proven clinical value when evaluating patients with carotid atherosclerosis. In this systematic review, we will focus on the role of novel molecular imaging tracers in that assessment and their potential strengths to stratify stroke risk. We systematically searched PubMed, Embase, the Web of Science Core
-
Towards a More Inclusive Future: A Comprehensive Assessment of Gender Diversity in Nuclear Medicine Education, Training and Workforce Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-11-18 Anita Brink MD PhD, Ora Israel MD PhD, Helen Nadel MD PhD, Manuela Arevalo-Pardo LLB, Oleksandr Kalinchuk MS, Enrique Estrada-Lobato MD, Maria Naydenova MSc MBA, Milena Drace BA MSc, Diana Paez MD MsEd
The field of nuclear medicine has undergone remarkable advances, particularly with the introduction of new devices, radionuclides for imaging and therapy, new clinical applications, and emergence of medical evidence. As this dynamic field continues its rapid expansion, there is an urgent need to increase the number of well-trained professionals globally. Consequently, advocating for nuclear medicine
-
A Practical Guide to the Pearls and Pitfalls of PSMA PET Imaging Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-11-18 Andrew F. Voter, Rudolf A. Werner, Hatice Savas, Andrei Gafita, Ashley E. Ross, Michael A. Gorin, Lilja B. Solnes, Martin G. Pomper, Steven P. Rowe, Sara Sheikhbahaei
Prostate-specific membrane antigen (PSMA)-targeted PET agents have revolutionized the care of patients with prostate cancer, supplanting traditional methods of imaging prostate cancer, and improving the selection and delivery of therapies. This has led to a rapid expansion in both the number of PSMA PET scans performed and the imaging specialists required to interpret those scans. To aid those imagers
-
PET/CT in Inflammatory and Auto-immune Disorders: Focus on Several Key Molecular Concepts, FDG, and Radiolabeled Probe Perspectives Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-11-14 Florent L Besson, Gaetane Nocturne, Nicolas Noël, Olivier Gheysens, Riemer H.J.A. Slart, Andor W.J.M. Glaudemans
Chronic immune diseases mainly include autoimmune and inflammatory diseases. Managing chronic inflammatory and autoimmune diseases has become a significant public health concern, and therapeutic advancements over the past 50 years have been substantial. As therapeutic tools continue to multiply, the challenge now lies in providing each patient with personalized care tailored to the specifics of their
-
PSMA PET/CT Versus mpMRI for the Detection of Clinically Significant Prostate Cancer: An Updated Overview Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-11-10 Matteo Caracciolo, Angelo Castello, Egesta Lopci
In the last years, PSMA-PET imaging and multiparametric MRI (mpMRI) have improved the clinical management of prostate cancer (PCa) patients. Currently, mpMRI is recommended by the EAU (European Association of Urology) guidelines for the primary diagnosis of PCa, whereas PSMA-PET is reserved for disease staging, particularly in high risk localized or locally advanced disease, as well as for biochemical
-
Advances in PET Imaging of the CXCR4 Receptor: [68Ga]Ga-PentixaFor Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-11-03 Liza Lindenberg, Mark Ahlman, Frank Lin, Esther Mena, Peter Choyke
[68Ga]Ga-PentixaFor, a PET agent targeting CXCR4 is emerging as a versatile radiotracer with promising applications in oncology, cardiology and inflammatory disease. Preclinical work in various cancer cell lines have demonstrated high specificity and selectivity. In human investigations of several tumors, the most promising applications may be in multiple myeloma, certain lymphomas and myeloproliferative
-
Functional Imaging in Musculoskeletal Disorders in Menopause Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-10-31 Luca Filippi MD, Riccardo Camedda MD, Viviana Frantellizzi MD PhD, Nicoletta Urbano MD, Giuseppe De Vincentis MD, Orazio Schillaci MD
Menopause-related musculoskeletal (MSK) disorders include osteoporosis, osteoarthritis (OA), sarcopenia and sarco-obesity. This review focuses on the applications of nuclear medicine for the functional imaging of the aforementioned clinical conditions. Bone Scan (BS) with Tc-labeled phosphonates, alone or in combination with MRI, can identify “fresh” vertebral collapse due to age-associated osteoporosis
-
Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [18F]F-FDG Tracers - Part I. PSMA, Choline, and DOTA Radiotracers Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-09-24 Seyed Ali Mirshahvalad, Roya Eisazadeh, Malihe Shahbazi-Akbari, Christian Pirich, Mohsen Beheshti
Artificial intelligence (AI) has evolved significantly in the past few decades. This thriving trend has also been seen in medicine in recent years, particularly in the field of imaging. Machine learning (ML), deep learning (DL), and their methods (eg, SVM, CNN), as well as radiomics, are the terminologies that have been introduced to this field and, to some extent, become familiar to the expert clinicians
-
Letter From the Editors Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-09-21 M. Michael Sathekge, Kirsten Bouchelouche
Abstract not available
-
Critical Appraisal of the Current Role of Myocardial Perfusion Imaging in the Management of Acute Chest Pain Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-09-16 Raffaele Giubbini, Barbara Paghera, Maurizio Dondi, Enrique Estrada Lobato, Amalia Peix, Diana Paez
This paper describes the evolution of nuclear cardiology techniques in the setting of acute coronary syndromes. Since the 1970s, the contribution of nuclear cardiology has been fundamental in delineating the physiopathology and diagnosis of acute myocardial infarction, when electrocardiogram (ECG) did not provide the diagnosis and when cardiac enzyme assessments were at a very early stage. In this
-
A Clinical Role of PET-MRI in Prostate Cancer? Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-08-29 Michael C.M. Gammel, Esteban L. Solari, Matthias Eiber, Isabel Rauscher, Stephan G. Nekolla
PET/MRI is a relevant application field for prostate cancer management, offering advantages in early diagnosis, staging, and therapy planning. Despite drawbacks such as higher costs, longer acquisition time, and the need for skilled personnel, the technical integration of PET and MRI provides valuable information for detecting primary tumors, identifying metastases, and characterizing the disease,
-
[15O]H2O PET: Potential or Essential for Molecular Imaging? Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-08-26 Riemer H.J.A. Slart, T. Samara Martinez-Lucio, Hendrikus H. Boersma, Ronald H. Borra, Bart Cornelissen, Rudi A.J.O. Dierckx, Magdalena Dobrolinska, Janine Doorduin, Paola A. Erba, Andor W.J.M. Glaudemans, Bruno Lima Giacobbo, Gert Luurtsema, Walter Noordzij, Joyce van Sluis, Charalampos Tsoumpas, Adriaan A. Lammertsma
Imaging water pathways in the human body provides an excellent way of measuring accurately the blood flow directed to different organs. This makes it a powerful diagnostic tool for a wide range of diseases that are related to perfusion and oxygenation. Although water PET has a long history, its true potential has not made it into regular clinical practice. The article highlights the potential of water
-
Is There a Role of Interim PSMA PET in Chemotherapy of Prostate Cancer? Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-08-18 Riccardo Laudicella, Matteo Bauckneht, Irene A. Burger
While RECIST 1.1 is well established in radiological response assessment, it is of limited use in prostate cancer (PCa) considering that the disease is often seen only as sclerotic bone changes on conventional imaging. Therefore, a molecular imaging-based response assessment including bone scans has been proposed and used in clinical trials, however, due to the flare phenomenon on bone scans this assessment
-
Bone Metastasis in Prostate Cancer: Bone Scan Versus PET Imaging Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-08-17 Nasibeh Mohseninia, Nazanin Zamani-Siahkali, Sara Harsini, Ghasemali Divband, Christian Pirich, Mohsen Beheshti
Prostate cancer is the second most common cause of malignancy among men, with bone metastasis being a significant source of morbidity and mortality in advanced cases. Detecting and treating bone metastasis at an early stage is crucial to improve the quality of life and survival of prostate cancer patients. This objective strongly relies on imaging studies. While CT and MRI have their specific utilities
-
Standardized PSMA-PET Imaging of Advanced Prostate Cancer Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-08-10 R. Seifert, A. Gafita, T. Telli, Andrew Voter, K. Herrmann, Martin Pomper, B. Hadaschik, Steven P. Rowe, W.P. Fendler
Imaging of advanced prostate cancer is a challenging task, as it requires longitudinal characterization of disease extent in a standardized way to enable appropriate treatment selection and evaluation of treatment efficacy. In the last years, prostate-specific membrane antigen (PSMA)-PET/CT has become the reference standard examination for patients with advanced prostate cancer. Together with the rise
-
PSMA PET for Detection of Recurrence Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-08-09 Heying Duan, Andrei Iagaru
Prostate cancer (PC) is a significant health concern worldwide, with high incidence and mortality rates. Early and accurate detection and localization of recurrent disease at biochemical recurrence (BCR) is critical for guiding subsequent therapeutic decisions and improving patient outcomes. At BCR, conventional imaging consisting of CT, MRI, and bone scintigraphy are recommended by US and European
-
How to Report PSMA PET Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-08-08 Mina Swiha, Narjess Ayati, Daniela E. Oprea-Lager, Francesco Ceci, Louise Emmett
Prostate cancer (PCa) is the most common cancer diagnosed in men in most developed countries and a leading cause of cancer-related morbidity and mortality. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) has become a valuable tool in the staging and assessment of disease recurrence in PCa, and more recently for assessment for treatment eligibility to PSMA radioligand therapy
-
Prognostic Value of PSMA PET/CT in Prostate Cancer Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-07-22 Ismaheel O. Lawal, Honest Ndlovu, Mankgopo Kgatle, Kgomotso M.G. Mokoala, Mike M. Sathekge
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in the majority of prostate cancer (PCa). PSMA has an enzymatic function that makes metabolic substrates such as folate available for utilization by PCa cells. Intracellular folate availability drives aggressive tumor phenotype. PSMA expression is, therefore, a marker of aggressive tumor biology. The large extracellular
-
PSMA PET/CT for Primary Staging of Prostate Cancer - An Updated Overview Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-07-22 Mads Ryø Jochumsen, Kirsten Bouchelouche
Prostate-specific membrane antigen PET/CT for primary staging of prostate cancer is becoming increasingly popular due to simultaneous assessment of whole-body disease burden, with superior sensitivity and specificity for detecting metastases compared to conventional imaging. PSMA PET in combination with multiparametric MRI (mpMRI) improves the sensitivity of assessment of extra-prostatic extension
-
Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-07-18 Suresh Alati, Rajan Singh, Martin G. Pomper, Steven P. Rowe, Sangeeta Ray Banerjee
Prostate cancer is a leading cause of cancer death in men worldwide. Among the various treatment options, radiopharmaceutical therapy has shown notable success in metastatic, castration-resistant disease. Radiopharmaceutical therapy is a systemic approach that delivers cytotoxic radiation doses precisely to the malignant tumors and/or tumor microenvironment. Therapeutic radiopharmaceuticals are composed
-
Letter from the Editors Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-07-13 Kirsten Bouchelouche, M. Michael Sathekge
Abstract not available
-
Imaging of Gastrointestinal Bleeding: An Update Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-07-12 Chen Sheng Low, Nikhil Rao
Imaging of gastrointestinal bleeding crucial in the diagnosis of occult gastrointestinal bleeding. Gastrointestinal bleeding scintigraphy is a well-established study to aid localisation of gastrointestinal bleeding site. This article discusses about the use of gastrointestinal bleeding scintigraphy in its current practice with emphasis on radiopharmaceutical, imaging techniques, interpretation and
-
Special Challenges in PET Imaging of Ectothermic Vertebrates Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-07-11 Aage Kristian Olsen Alstrup, Morten Busk, Anita Dittrich, Kasper Hansen, Tobias Wang, Mads Damkjær, Johnnie Bremholm Andersen, Henrik Lauridsen
The bulk of biomedical positron emission tomography (PET)-scanning experiments are performed on mammals (ie, rodents, pigs, and dogs), and the technique is only infrequently applied to answer research questions in ectothermic vertebrates such as fish, amphibians, and reptiles. Nevertheless, many unique and interesting physiological characteristics in these ectothermic vertebrates could be addressed
-
Role of FDG PET/CT in Management of Patients with Prostate Cancer Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-07-01 Duncan E.K. Sutherland, Arun A. Azad, Declan G. Murphy, Renu S. Eapen, Louise Kostos, Michael S. Hofman
Prostate cancer is the second most common cancer in men worldwide. [18F]FDG PET/CT imaging, a well-known and effective technique for detecting malignancies, has not been considered a useful tool for prostate cancer imaging by many because of its perceived low [18F]FDG uptake. Incidentally detected focal [18F]FDG uptake in the prostate is not uncommon, and typically benign. Imaging features that would
-
Future Imaging of Prostate Cancer: Do We Need More Than PSMA PET/CT? Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-07-01 Luigia Vetrone, Emilia Fortunati, Paolo Castellucci, Stefano Fanti
In the setting of prostate cancer (PCa), many different imaging modalities are available to correctly assess staging, restaging, treatment response and radio-ligand therapy recruitment. The introduction of fluoride or gallium-labelled prostate specific membrane antigen (PSMA) made a revolution in PCa management, also due to its possible theragnostic use. Nowadays PSMA-PET/CT is a fundamental tool for
-
PSMA PET/CT for Response Assessment of 177Lu-PSMA Therapy Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-06-23 Philipp E. Hartrampf, Sebastian E. Serfling, Kerstin Michalski, Andreas K. Buck, Rudolf A. Werner
Prostate-specific membrane antigen (PSMA) PET/CT has been widely integrated into the management of prostate cancer (PCa) patients with biochemical recurrence, is increasingly used for initial staging in high-risk patients prior to surgery or to identify candidates for PSMA-targeted radioligand therapy (RLT). To date, monitoring response in PCa patients in prospective studies remains the domain of conventional
-
Applications of Artificial Intelligence in PSMA PET/CT for Prostate Cancer Imaging Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-06-23 Sarah Lindgren Belal, Sophia Frantz, David Minarik, Olof Enqvist, Erik Wikström, Lars Edenbrandt, Elin Trägårdh
Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has emerged as an important imaging technique for prostate cancer. The use of PSMA PET/CT is rapidly increasing, while the number of nuclear medicine physicians and radiologists to interpret these scans is limited. Additionally, there is variability in interpretation among readers. Artificial intelligence
-
Hepato-Biliary Imaging in an Acute Setting: Is There a Role for Nuclear Medicine? Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-06-01 Luca Filippi, Luca Urso, Orazio Schillaci, Laura Evangelista
Nuclear medicine (NM) is not commonly considered as a first-line imaging modality in hepato-biliary (HB) emergencies. The aim of this review is to provide an update on the potential of NM for the imaging of HB emergencies. 99mTc-HIDA scintigraphy showed high diagnostic accuracy for acute cholecystitis, thus being particularly useful in patients at high-risk for surgery due to comorbidities and with
-
Preclinical Imaging of Cardiovascular Disesase Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-06-01 Stephan G. Nekolla, Christoph Rischpler, Takahiro Higuchi
Noninvasive imaging techniques, such as SPECT, PET, CT, echocardiography, or MRI, have become essential in cardiovascular research. They allow for the evaluation of biological processes in vivo without the need for invasive procedures. Nuclear imaging methods, such as SPECT and PET, offer numerous advantages, including high sensitivity, reliable quantification, and the potential for serial imaging
-
Nuclear Medicine Preclinical Research: The Role of Cell Cultures Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-06-01 Morten Busk, Steffen Sinning, Aage K.O. Alstrup, Ole L. Munk, Mikkel H. Vendelbo
Cell lines are essential in biomedical research due to their adaptability and precise simulation of physiological and pathophysiological conditions. Cell culture techniques have greatly advanced our understanding of biology in various fields and are widely regarded as a reliable and durable tool. Their diverse applications make them indispensable in scientific research. Radiation-emitting compounds
-
Practice of 18F-FDG-PET/CT in ICU Patients: A Systematic Review Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-05-29 Bram van Leer, Nick D. van Rijsewijk, Maarten W.N. Nijsten, Riemer H.J.A. Slart, Janesh Pillay, Andor W.J.M. Glaudemans
18F-FDG-PET/CT imaging has become a key tool to evaluate infectious and inflammatory diseases. However, application of 18F-FDG-PET/CT in patients in the intensive care unit (ICU) is limited, which is remarkable since the development of critical illness is closely linked to infection and inflammation. This limited use is caused by perceived complexity and risk of planning and executing 18F-FDG-PET/CT
-
Role of Functional SPECT and PET in Renal Emergencies Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-05-24 Takahiro Higuchi, Philipp E. Hartrampf, Andreas K. Buck, Martin G. Pomper, Steven P. Rowe, Sebastian E. Serfling, Rudolf A. Werner
Renal scintigraphy is a centerpiece of nuclear medicine and is also commonly applied for (peri-)acute care. In this regard, referrals by the treating physician include: I.) acute obstructions caused by gradual and infiltrative tumor growth or renal off-target effects under anti-tumor treatment, II.) functional issues in infants, for example, structural abnormalities such as duplex kidneys or uroliths
-
Academic integrity and artificial intelligence: is ChatGPT hype, hero or heresy? Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-05-22 Geoffrey M. Currie
Academic integrity in both higher education and scientific writing has been challenged by developments in artificial intelligence. The limitations associated with algorithms have been largely overcome by the recently released ChatGPT; a chatbot powered by GPT-3.5 capable of producing accurate and human-like responses to questions in real-time. Despite the potential benefits, ChatGPT confronts significant
-
Update on Pediatric Nuclear Medicine in Acute Care Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-05-19 Joshua Chin, Reza Vali, Martin Charron, Amer Shammas
Various radiopharmaceuticals are available for imaging pediatric patients in the acute care setting. This article focuses on the common applications used on a pediatric patient in acute care. To confirm the clinical diagnosis of brain death, brain scintigraphy is considered accurate and has been favorably compared with other methods of detecting the presence or absence of cerebral blood flow. Ventilation-perfusion
-
Functional Imaging of Testicular Torsion Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-05-18 Qaisar H. Siraj
This article discusses the current clinical role and scope of functional radionuclide imaging using testicular perfusion scintigraphy with 99mTc-pertechnetate in patients presenting with an acute hemiscrotum for an early and reliable diagnosis of testicular torsion. The technique of testicular perfusion scintigraphy is described, and the characteristic findings are detailed with examples. The imaging
-
Letter from the Editors Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-05-13 M. Michael Sathekge, Kirsten Bouchelouche
Abstract not available
-
Preclinical Evaluation of Novel PET Probes for Dementia Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-05-05 Romy Cools, Kobe Kerkhofs, Renan C.F. Leitao, Guy Bormans
The development of novel PET imaging agents that selectively bind specific dementia-related targets can contribute significantly to accurate, differential and early diagnosis of dementia causing diseases and support the development of therapeutic agents. Consequently, in recent years there has been a growing body of literature describing the development and evaluation of potential new promising PET
-
Scintigraphic Diagnosis of Acute Pulmonary Embolism: From Basics to Best Practices Semin. Nucl. Med. (IF 4.9) Pub Date : 2023-05-03 Pierre-Yves Le Roux, Romain Le Pennec, Pierre-Yves Salaun, Lionel S. Zuckier
In this article the technique, interpretation, and diagnostic performance of scintigraphy for the diagnosis of acute pulmonary embolism (PE) are reviewed. Lung scintigraphy has stood the test of time as a reliable and validated examination for the determination of PE. Ventilation/perfusion (V/Q) lung scintigraphy assesses the functional consequences of the clot on its downstream vascular bed in conjunction